Urogen Pharma (URGN) Institutional Ownership

91.29% of Urogen Pharma's stock is owned by institutional investors. Learn more on URGN's institutional investor holdings.

Of the 136 institutional investors that purchased Urogen Pharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Paradigm Biocapital Advisors LP ($4.47M), Toronto Dominion Bank ($3.50M), RA Capital Management L.P. ($3.21M), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC ($3.04M), Soleus Capital Management L.P. ($2.19M), Vestal Point Capital LP ($2.15M), and SG Americas Securities LLC ($1.66M).

Institutional investors have bought a total of 18,104,720 shares in the last 24 months. This purchase volume represents approximately $346.28M in transactions.

Of the 52 institutional investors that sold Urogen Pharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Menora Mivtachim Holdings LTD. ($1.15M), Millennium Management LLC ($894.79K), Healthcare of Ontario Pension Plan Trust Fund ($738.03K), Tang Capital Management LLC ($650K), Adage Capital Partners GP L.L.C. ($447K), JPMorgan Chase & Co. ($388.27K), and Harel Insurance Investments & Financial Services Ltd. ($291.21K).

Institutional investors have sold a total of 6,428,821 shares in the last 24 months. This volume of shares sold represents approximately $123.26M in transactions.